Cannabis Science Supports House Minority Leader Nancy Pelosi Historic Statement to President Obama Supporting Medical Cann

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB: CBIS.ob - News), a pioneering U.S. biotech company developing pharmaceutical cannabis products, supports House Minority Leader Nancy Pelosi D-San Francisco Historic Statement to President Obama supporting Medical Cannabis and the Fight for Patient Rights.

Quoted in several news sources including but not limited to the following:

The Huffington Post:

and MediaNews Group:

House Minority Leader Nancy Pelosi D-San Francisco Historic Statement to President Obama stated the following;

“Access to medicinal marijuana for individuals who are ill or enduring difficult and painful therapies is both a medical and a states' rights issue. Sixteen states, including our home state of California and the District of Columbia have adopted medicinal marijuana laws – most by a vote of the people.

I have strong concerns about the recent actions by the federal government that threatens the safe access of medicinal marijuana to alleviate the suffering of patients in California, and undermine a policy that has been in place under which the federal government did not pursue individuals whose actions complied with state laws providing for medicinal marijuana.

Proven medicinal uses of marijuana include improving the quality of life for patients with cancer, HIV/AIDS, multiple sclerosis, and other severe medical conditions.

I am pleased to join organizations that support legal access to medicinal marijuana, including the American Nurses Association, the Lymphoma Foundation of America, and the AIDS Action Council.

Medicinal marijuana alleviates some of the most debilitating symptoms of AIDS, including pain, wasting, and nausea. The opportunity to ease the suffering of people who are seriously ill or enduring difficult and painful therapies is an opportunity we must not ignore.

For these reasons, I have long supported efforts in Congress to advocate federal policies that recognize the scientific evidence and clinical research demonstrating the medical benefits of medicinal marijuana, that respects the wishes of the states in providing relief to ill individuals, and that prevents the federal government from acting to harm the safe access of medicinal marijuana provided under state law. I will continue to strongly support those efforts.”

Dr. Robert Melamede stated, “It’s about time members of congress spoke out in favor of democracy. The people in states like California and Colorado have spoken through their ballots, the very basis of democracy. This is a presidential election year. As soon as the voting public demands medical marijuana as a condition for election, things will rapidly change. We are not surprised by Nancy Pelosi’s statement in view of the low approval ratings that our politicians have. We expect to continue to see more and more politicians come out in favor of the Medical Cannabis industry over the next few months. Let’s face it, prohibition and its associated black market is a source of funding for terrorism and therefore should be illegal.

Our internal models suggest that the medical cannabis industry may lower unemployment by 11.6% or more and increase GDP. The Cannabis Industry can help our great country while at the same time help people with Cancer and help soldiers with PTSD. All of these topics are election issues, which tie into the Medical Cannabis Industry and should have a positive impact on Cannabis Science.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.


Cannabis Science
Robert Kane
Vice President of Investor Relations
[email protected]
Dr. Robert Melamede, Ph.D.
[email protected]

KEYWORDS:   United States  North America  California  Colorado

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Clinical Trials  Public Policy/Government  Healthcare Reform  Oncology  Professional Services  Consulting